November 2024
1. KILLOCK D
   First-line triplet therapy for advanced-stage PIK3CA-mutant HR(+) breast cancer improves outcomes.
   Nat Rev Clin Oncol. 2024 Nov 12. doi: 10.1038/s41571-024-00968.
   

   >> Share

   
   
2. DRAGO J, Modi S
   Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
   Nat Rev Clin Oncol. 2024 Nov 6. doi: 10.1038/s41571-024-00963.
   

   >> Share

   
   
3. WAKS AG, Martinez-Saez O, Tarantino P, Braso-Maristany F, et al
   Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.
   Nat Rev Clin Oncol. 2024;21:818-832.
   

   >> Share

   
   August 2024
4. LLOYD MR, Jhaveri K, Kalinsky K, Bardia A, et al
   Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.
   Nat Rev Clin Oncol. 2024 Aug 23. doi: 10.1038/s41571-024-00935.
   

   >> Share

   
   
5. MARRA A, Chandarlapaty S, Modi S
   Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
   Nat Rev Clin Oncol. 2024 Aug 2. doi: 10.1038/s41571-024-00933.
   

   >> Share

   
   July 2024
6. YOON J, Oh DY
   HER2-targeted therapies beyond breast cancer - an update.
   Nat Rev Clin Oncol. 2024 Jul 22. doi: 10.1038/s41571-024-00924.
   

   >> Share

   
   June 2024
7. KILLOCK D
   ALND can be safely omitted for patients with sentinel-node macrometastases.
   Nat Rev Clin Oncol. 2024;21:402.
   

   >> Share

   
   May 2024
8. DIECI MV, Guarneri V
   Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain.
   Nat Rev Clin Oncol. 2024 May 22. doi: 10.1038/s41571-024-00907.
   

   >> Share

   
   April 2024
9. SIDAWAY P
   KN046 shows tolerability and activity in TNBC.
   Nat Rev Clin Oncol. 2024;21:251.
   

   >> Share

   
   March 2024
10. KONTOS D
    The promise of AI in personalized breast cancer screening: are we there yet?
    Nat Rev Clin Oncol. 2024 Mar 12. doi: 10.1038/s41571-024-00877.
    

    >> Share

    
    January 2024
11. MARRA A, Chandarlapaty S, Modi S
    Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.
    Nat Rev Clin Oncol. 2024 Jan 8. doi: 10.1038/s41571-023-00849.
    

    >> Share

    
    December 2023
12. BERTON GIACHETTI PPM, Curigliano G
    Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
    Nat Rev Clin Oncol. 2023 Dec 19. doi: 10.1038/s41571-023-00854.
    

    >> Share

    
    
13. MORRISON L, Loibl S, Turner NC
    The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
    Nat Rev Clin Oncol. 2023 Dec 11. doi: 10.1038/s41571-023-00840.
    

    >> Share

    
    November 2023
14. SIDAWAY P
    Sacituzumab govitecan improves OS in heavily pretreated patients.
    Nat Rev Clin Oncol. 2023;20:734.
    

    >> Share

    
    October 2023
15. ARECCO L, Lambertini M
    Safety of interrupting adjuvant endocrine therapy to conceive: early data are POSITIVE.
    Nat Rev Clin Oncol. 2023;20:662-663.
    

    >> Share

    
    July 2023
16. SIDAWAY P
    T-DXd is effective after T-DM1.
    Nat Rev Clin Oncol. 2023;20:426.
    

    >> Share

    
    February 2023
17. O'LEARY B
    PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching.
    Nat Rev Clin Oncol. 2023;20:67-68.
    

    >> Share

    
    October 2022
18. AGOSTINETTO E, Gligorov J, Piccart M
    Systemic therapy for early-stage breast cancer: learning from the past to build the future.
    Nat Rev Clin Oncol. 2022 Oct 17. pii: 10.1038/s41571-022-00687.
    

    >> Share

    
    July 2022
19. VASAN N, Cantley LC
    At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy.
    Nat Rev Clin Oncol. 2022;19:471-485.
    

    >> Share

    
    April 2022
20. SIDAWAY P
    Pembrolizumab improves EFS in TNBC.
    Nat Rev Clin Oncol. 2022;19:220.
    

    >> Share

    
    March 2022
21. SOUTHEY MC, Dugue PA
    Improving breast cancer risk prediction with epigenetic risk factors.
    Nat Rev Clin Oncol. 2022 Mar 29. pii: 10.1038/s41571-022-00622.
    

    >> Share

    
    November 2021
22. BIANCHINI G, De Angelis C, Licata L, Gianni L, et al
    Treatment landscape of triple-negative breast cancer - expanded options, evolving needs.
    Nat Rev Clin Oncol. 2021 Nov 9. pii: 10.1038/s41571-021-00565.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share